We are live on ! Find out more
IMNM icon

Immunome

28 hedge funds and large institutions have $4.85M invested in Immunome in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

17% more funds holding

Funds holding: 24 → 28 (+4)

0% more call options, than puts

Call options by funds: $6K | Put options by funds: $6K

2.41% less ownership

Funds ownership: 19.73% → 17.32% (-2.4%)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

88% less capital inflows, than outflows

Capital inflows: $155K | Capital outflows: $1.33M

Holders
28
Holders Change
+4
Holders Change %
+16.67%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
6
Closed
2
Calls
$6​K
Puts
$6​K
Net Calls
–
Net Calls Change
-⁠$231​K

IMNM Hedge Fund Activity: Q4 2022 in Review

28 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q4 2022, worth a combined $4.85M — down 55% from $10.7M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new IMNM positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 6 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $88.9K. The largest seller was Prentice Capital Management, cutting an estimated $1.18M.

  • 28 institutional investors held Immunome (IMNM) as of Q4 2022, up from 24 in Q3 2022.
  • Funds reported $4.85M of Immunome stock for Q4 2022, down 55% quarter-over-quarter.
  • 4 funds opened new Immunome positions in Q4 2022 and 2 closed out, a net change of +2 holders.
  • The largest Immunome buyer in Q4 2022 was Susquehanna International Group, an estimated $88.9K added.
  • The largest Immunome seller in Q4 2022 was Prentice Capital Management, an estimated $1.18M sold.

Based on aggregated 13F filings for Q4 2022.